MedTrace Logo

EU/LA Pearl Index Study - Transdermal Contraceptive Patch

NCT00914693 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1694

Last updated 2014-12-05

No results posted yet for this study

Summary

The aim of the present study is to prove efficacy and safety of a new contraceptive patch.

Conditions

  • Contraception

Interventions

DRUG

Ethinylestradiol/Gestodene (BAY86-5016)

7-day patch containing 0.55 mg ethinylestradiol (EE) and 2.1 mg gestodene (GSD) in a 21-day regimen

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2011-09-30
Completion
2011-09-30

Countries

  • Argentina
  • Australia
  • Chile
  • France
  • Germany
  • Italy
  • Mexico
  • Spain

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00914693 on ClinicalTrials.gov